Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Research & Development (2016 - 2025)

KalVista Pharmaceuticals' Research & Development history spans 11 years, with the latest figure at $15.9 million for Q2 2025.

  • On a quarterly basis, Research & Development fell 37.06% to $15.9 million in Q2 2025 year-over-year; TTM through Apr 2025 was $84.4 million, a 2.09% decrease, with the full-year FY2025 number at $71.7 million, down 16.78% from a year prior.
  • Research & Development hit $15.9 million in Q2 2025 for KalVista Pharmaceuticals, down from $16.6 million in the prior quarter.
  • Over the last five years, Research & Development for KALV hit a ceiling of $26.6 million in Q3 2024 and a floor of $9.1 million in Q1 2021.
  • Historically, Research & Development has averaged $19.3 million across 4 years, with a median of $19.2 million in 2023.
  • Biggest five-year swings in Research & Development: surged 37.85% in 2024 and later plummeted 37.06% in 2025.
  • Tracing KALV's Research & Development over 4 years: stood at $9.1 million in 2021, then skyrocketed by 109.84% to $19.1 million in 2023, then fell by 12.99% to $16.6 million in 2024, then decreased by 4.33% to $15.9 million in 2025.
  • Business Quant data shows Research & Development for KALV at $15.9 million in Q2 2025, $16.6 million in Q4 2024, and $26.6 million in Q3 2024.